FAMILIA DE CARDIOVERSORESDESFIBRILADORES IMPLANTABLESINTICA NEO/ ILIVIA NEO-BIOTRONIK
INTICANEO/ILIVIANEOPERTENECEAUNAFAMILIADEDESFIBRILADORESAUTOMÁTICOSIMPLANTABLES(DAI).ELOBJETIVOPRINCIPALDE LA TERAPIA ES PREVENIR LA MUERTECARDÍACASÚBITA.ADEMÁS,ELDISPOSITIVOES CAPAZ DE TRATAR ARRITMIAS PORBRADICARDIA Y TERAPIA DERESINCRONIZACIÓN CARDÍACA CONESTIMULACIÓN VENTRICULAR MULTISITIO.
INTICANEO/ILIVIANEOBELONGS TO A FAMILY OF IMPLANTABLE CARDIOVERTERATORS (ICD). THE MAIN GOAL OF THERAPY IS TO PREVENT SUDDEN CARDIAC DEATH. IN ADDITION, THE DEVICE IS CAPABLE OF TREATING PORBRADYCARDIA ARRHYTHMIAS AND CARDIAC RESYNCHRONIZATION THERAPY WITH MULTISITE VENTRICULAR STIMULATION.
- Risk Class / Clase de Riesgo
- Clase III
- Product Type (Spanish)
- II. PROTESIS, ÓRTESIS Y AYUDAS FUNCIONALES
- Product Type (English)
- II. PROSTHETICS, ORTHOSES AND FUNCTIONAL AIDS
- Trade Name (Spanish)
- CARDIOVERSOR DESFIBRILADORIMPLANTABLE
- Trade Name (English)
- CARDIOVERSOR DESFIBRILADORIMPLANTABLE
- Analysis ID
- 897C2021 SSA
- Registration Date
- May 26, 2021
- Name (Spanish)
- ASESORES MÉDICOBIOLÓGICOS, S.A. DEC.V.
- Name (English)
- ASESORES MÉDICOBIOLÓGICOS, S.A. DEC.V.
Access comprehensive regulatory information for FAMILIA DE CARDIOVERSORESDESFIBRILADORES IMPLANTABLESINTICA NEO/ ILIVIA NEO-BIOTRONIK (FAMILY OF CARDIOVERSORDEFIBRILLATORSINBRILLATORSINTICA NEO/ ILIVIA NEO-BIOTRONIK) in the Mexico medical device market through Pure Global AI's free database. This Clase III medical device is registered under COFEPRIS analysis ID 897C2021 SSA and manufactured by ASESORES MÉDICOBIOLÓGICOS, S.A. DEC.V.. The device was registered on May 26, 2021.
This page provides complete registration details including product type (II. PROSTHETICS, ORTHOSES AND FUNCTIONAL AIDS), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.